tovorafenib 25 MG in 1 mL Powder for Oral Suspension
- RxCUI
- 2682439
- RxNorm name
- tovorafenib 25 MG in 1 mL Powder for Oral Suspension
- Display name
- tovorafenib 25 MG in 1 mL Powder for Oral Suspension
- Full name
- tovorafenib 25 MG in 1 mL Powder for Oral Suspension
- Term type
- PSN
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:26
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| OJEMDA | TOVORAFENIB | Day One Biopharmaceuticals, Inc. | ea3a9631-3a66-6a7c-e053-2995a90ae2ad | 2025-09-02 | Warnings, Adverse reactions | 2682439 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| ea3a9631-3a66-6a7c-e053-2995a90ae2ad | tovorafenib 25 MG in 1 mL Powder for Oral Suspension [PSN] · tovorafenib 300 MG Powder for Oral Suspension [SCD] · tovorafenib 25 MG per 1 ML Powder for Oral Suspension [SY] · tovorafenib 300 MG per 12 ML Powder for Oral Suspension [SY] | 4 | 9 | These highlights do not include all the information needed to use OJEMDA safely and effectively. See full prescribing information for OJEMDA. OJEMDA (tovorafenib) tablets, for oral use OJEMDA (tovorafenib) for oral suspension Initial U.S. Approval: 2024 | 20250902 |